Literature DB >> 12045507

Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections.

.   

Abstract

UNAIDS and WHO produce biannual country-specific estimates of HIV/AIDS and its impact. These estimates are based on methods and assumptions that reflect the best understanding of HIV epidemiology and demography at the time. Where significant advances are made in epidemiological and demographic research, the methods and assumptions must evolve to match these advances. UNAIDS established an Epidemiology Reference Group in 1999 to advise them and other organisations on HIV epidemiology and methods for making estimates and projections of HIV/AIDS. During the meeting of the reference group in 2001, four priority areas were identified where methods and assumptions should be reviewed and perhaps modified: a) models of the HIV epidemic, b) survival of adults with HIV-1 in low and middle income countries, c) survival of children with HIV-1 in low and middle income countries, and d) methods to estimate numbers of AIDS orphans. Research and literature reviews were carried out by Reference Group members and invited specialists, prior to meetings held during 2001-2. Recommendations reflecting the consensus of the meeting participants on the four priority areas were determined at each meeting. These recommendations were followed in UNAIDS and WHO development of country-specific estimates of HIV/AIDS and its impact for end of 2001.

Entities:  

Mesh:

Year:  2002        PMID: 12045507     DOI: 10.1097/00002030-200206140-00024

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  48 in total

1.  More on the cohort-component model of population projection in the context of HIV/AIDS: A Leslie matrix representation and new estimates.

Authors:  Jason R Thomas; Samuel J Clark
Journal:  Demogr Res       Date:  2011-07-05

2.  HBV Infection Among HIV-Infected Cohort and HIV-Negative Hospital Attendees in South Western Nigeria.

Authors:  Moses Olubusuyi Adewumi; Emmanuel Donbraye; Waidi Folorunso Sule; Olaniran Olarinde
Journal:  Afr J Infect Dis       Date:  2015

3.  The 2005 Workbook: an improved tool for estimating HIV prevalence in countries with low level and concentrated epidemics.

Authors:  R Lyerla; E Gouws; J M García-Calleja; E Zaniewski
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

Review 4.  Improving projections at the country level: the UNAIDS Estimation and Projection Package 2005.

Authors:  T Brown; N C Grassly; G Garnett; K Stanecki
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  Improved plausibility bounds about the 2005 HIV and AIDS estimates.

Authors:  M Morgan; N Walker; E Gouws; K A Stanecki; J Stover
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

Review 6.  Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics.

Authors:  P D Ghys; E Kufa; M V George
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

7.  Can we obtain realistic HIV/AIDS estimates for India?

Authors:  Arni S Srinivasa Rao
Journal:  J Biosci       Date:  2003-06       Impact factor: 1.826

8.  How fast could HIV change gene frequencies in the human population?

Authors:  Deborah Cromer; Steven M Wolinsky; Angela R McLean
Journal:  Proc Biol Sci       Date:  2010-03-10       Impact factor: 5.349

9.  Estimating the number of people living with HIV/AIDS in China: 2003-09.

Authors:  Ning Wang; Lu Wang; Zunyou Wu; Wei Guo; Xinhua Sun; Katharine Poundstone; Yu Wang
Journal:  Int J Epidemiol       Date:  2010-12       Impact factor: 7.196

10.  Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.

Authors:  Martin W G Brinkhof; Andrew Boulle; Ralf Weigel; Eugène Messou; Colin Mathers; Catherine Orrell; François Dabis; Margaret Pascoe; Matthias Egger
Journal:  PLoS Med       Date:  2009-04-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.